Cancer Research Prevention Award  Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alemán, C.
Right arrow Articles by Gottesman, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alemán, C.
Right arrow Articles by Gottesman, M. M.
[Cancer Research 63, 3084-3091, June 15, 2003]
© 2003 American Association for Cancer Research


Biochemistry and Biophysics

P-Glycoprotein, Expressed in Multidrug Resistant Cells, Is Not Responsible for Alterations in Membrane Fluidity or Membrane Potential1

Claudina Alemán, Jean-Philippe Annereau, Xing-Jie Liang, Carol O. Cardarelli, Barbara Taylor, Jun Jie Yin, Adorjan Aszalos and Michael M. Gottesman2

Laboratory of Cell Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892-4254 [C. A., J-P. A., X-J. L., C. O. C., A. A., M. M. G.]; FACS Core Facility, National Cancer Institute, NIH, Bethesda, Maryland 20892-4255 [B. T.]; and Instrumentation and Biophysics Branch, Center for Food Safety and Applied Nutrition, College Park, Maryland 20740-3835 [J. J. Y.]

Expression of P-glycoprotein (P-gp), the multidrug resistance (MDR) 1 gene product, can lead to MDR in tumors. However, the physiological role of P-gp in normal tissues is not well understood. Previous studies on multidrug-resistant cells have suggested changes in membrane fluidity and membrane potential associated with P-gp expression, but interpretation of these studies is difficult, because most experimental cells have been selected for long periods in the presence of cytotoxic drugs and may have other host alterations. Therefore, we created two cell lines in which a transfected human MDR1 cDNA is repressed by tetracycline and induced in the absence of tetracycline. One cell line was derived from a mouse embryonic fibroblast cultured from a double (mdr1a/1b) knockout mouse, and the other was from a human HeLa cell line. Analysis of the kinetics of expression of P-gp showed that the mRNA had a half-life of ~4 h, and the protein had a half-life of ~16 h. P-gp cell surface expression (measured with monoclonal antibody MRK-16) and P-gp function (measured with a fluorescent substrate, rhodamine 123) was characterized by using fluorescence-activated cell sorting. No differences in membrane potential using the fluorescent probe oxonol or in membrane "fluidity" using fluorescent anisotropy probe or electron spin resonance probe were observed in the tet-repressible P-gp-expressing cells. In contrast, several drug-selected cells that express P-gp showed an increase in membrane fluidity and membrane potential. These results suggest that expression of P-gp per se has little effect on membrane fluidity or membrane potential, and it does not have H+ pump activity. The changes in these parameters observed in drug-selected cells must reflect other host adaptations to drug selection.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
I. Bottova, A. B. Hehl, S. Stefanic, G. Fabrias, J. Casas, E. Schraner, J. Pieters, and S. Sonda
Host Cell P-glycoprotein Is Essential for Cholesterol Uptake and Replication of Toxoplasma gondii
J. Biol. Chem., June 26, 2009; 284(26): 17438 - 17448.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. S. Carey, M. Gleason-Guzman, V. Gokhale, and L. H. Hurley
Psorospermin structural requirements for P-glycoprotein resistance reversal
Mol. Cancer Ther., November 1, 2008; 7(11): 3617 - 3623.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
W. Le Goff, M. Settle, D. J. Greene, R. E. Morton, and J. D. Smith
Reevaluation of the role of the multidrug-resistant P-glycoprotein in cellular cholesterol homeostasis
J. Lipid Res., January 1, 2006; 47(1): 51 - 58.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Y. Frank, A. Margaryan, Y. Huang, T. Schatton, A. M. Waaga-Gasser, M. Gasser, M. H. Sayegh, W. Sadee, and M. H. Frank
ABCB5-Mediated Doxorubicin Transport and Chemoresistance in Human Malignant Melanoma
Cancer Res., May 15, 2005; 65(10): 4320 - 4333.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Y. Frank, S. S. Pendse, P. H. Lapchak, A. Margaryan, D. Shlain, C. Doeing, M. H. Sayegh, and M. H. Frank
Regulation of Progenitor Cell Fusion by ABCB5 P-glycoprotein, a Novel Human ATP-binding Cassette Transporter
J. Biol. Chem., November 21, 2003; 278(47): 47156 - 47165.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.